SCHEMBL322928

SCHEMBL322928

O=C(O)N1CCc2ccccc2C1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.70
KMT2A Q03164 3/20 0.68
MEN1 O00255 2/20 0.68
MAPT P10636 1/20 0.68
TAAR1 Q96RJ0 1/20 0.68
SMN1; SMN2 Q16637 2/20 0.65
NPC1 O15118 1/20 0.65
TP53 P04637 1/20 0.65
RAB9A P51151 1/20 0.65
TMPRSS2 O15393 1/20 0.59
HTR1A P08908 1/20 0.59
ADRA2A P08913 1/20 0.59
CYP2D6 P10635 1/20 0.59
MAOA P21397 1/20 0.59
SLC6A2 P23975 1/20 0.59
HPGD P15428 4/20 0.58
LMNA P02545 3/20 0.58
ALDH1A1 P00352 2/20 0.58
HTT P42858 2/20 0.58
KEAP1 Q14145 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21496871 0.98 NOTUM (0.68) NOTUMKMT2AMEN1MAPTTAAR1
Hydrochloric Acid SCHEMBL28278641 0.96 NOTUM (0.66) NOTUMKMT2AMEN1MAPTTAAR1
SCHEMBL2124966 0.90 NOTUM (0.60) NOTUMKMT2AMEN1MAPTTAAR1
SCHEMBL23114040 0.89 RIPK1 (0.66) NOTUMKMT2AMEN1MAPTTAAR1
SCHEMBL27901981 0.86 NOTUM (0.72) NOTUMKMT2AMEN1MAPTTAAR1
SCHEMBL2533362 0.85 NOTUM (0.64) NOTUMKMT2AMEN1MAPTTAAR1
SCHEMBL29758685 0.85 NOTUM (0.64) NOTUMKMT2AMEN1MAPTTAAR1
SCHEMBL28253826 0.84 ALDH1A1 (0.59) NOTUMKMT2AMEN1MAPTTAAR1
SCHEMBL4290743 0.84 NOTUM (0.70) NOTUMKMT2AMEN1MAPTTAAR1
SCHEMBL4279383 0.83 HPGD (0.73) NOTUMKMT2AMEN1MAPTTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 781 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4301736-B1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2025-10-08 EP claimed
US-20240415819-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS QLi5 Therapeutics AG (DE) 2024-12-19 US claimed
CN-117024511-A Novel coronavirus-resistant peptidomimetic compound and preparation method thereof 烟台大学 2023-11-10 CN claimed
EP-4155296-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS Lead Discovery Center GmbH (DE) 2023-03-29 EP claimed
WO-2022104001-A1 EXPANDED PROTEIN LIBRARIES AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2022-05-19 WO claimed
CN-114364658-A Preparation method and composition of levo-praziquantel and chiral intermediate thereof 苏州同力生物医药有限公司 2022-04-15 CN claimed
EP-3956348-A1 PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY Feldan Bio Inc. (CA) 2022-02-23 EP claimed
WO-2020210916-A1 PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY FELDAN BIO INC. (CA) 2020-10-22 WO claimed
US-20190070149-A1 PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2019-03-07 US claimed
CN-107778230-A A kind of synthetic method of tetrahydro isoquinoline derivative 湖南华腾制药有限公司 2018-03-09 CN claimed
WO-1997031940-A1 ISOQUINOLINES USEFUL AS ANALGESICS ASTRA AKTIEBOLAG (SE) 1997-09-04 WO claimed
WO-1997023484-A1 NEW COMPOUNDS ASTRA AKTIEBOLAG (SE) 1997-07-03 WO claimed
WO-1997017050-A2 AN IMPROVED METHOD FOR PREPARATION OF SUBSTITUTED TETRAHYDROISOQUINOLINES MONSANTO COMPANY (US) 1997-05-15 WO claimed
US-5618792-A USEFUL FOR TREATING ACUTE RESPIRATORY DISEASES, AND MYOCARDIAL ISHCEMIA-REPERFUSION INJURY CORTECH, INC. (US) 1997-04-08 US claimed
WO-1996040742-A1 PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATEDDISORDERS ORTHO PHARMACEUTICAL CORPORATION (US) 1996-12-19 WO claimed
WO-1996040741-A1 PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS ORTHO PHARMACEUTICAL CORPORATION (US) 1996-12-19 WO claimed
WO-1996040748-A1 PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS ORTHO PHARMACEUTICAL CORPORATION (US) 1996-12-19 WO claimed
EP-0714909-A1 Composition for prophylaxis or treatment of pulmonary circulatory diseases Takeda Chemical Industries, Ltd. (JP) 1996-06-05 EP claimed
US-5523308-A SERINE PROTEASES INHIBITORS; ORAL ANTICOAGULANTS; CHEMICAL INTERMEDIATES; DIPEPTIDES ORTHO PHARMACEUTICAL CORPORATION 1996-06-04 US claimed
CN-1068333-A Has hydrazine analog derivative of pharmacologically active and preparation method thereof CIBA GEIGY AG (CH) 1993-01-27 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190070149-A1 PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO HTR5A, HTR2A, HTR1A NOTUM 2411/4885KMT2A 799/4885MEN1 3346/4885
US-20240415819-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS PSMB5, PSMA5, PSMB1 NOTUM 1110/4885KMT2A 3101/4885MEN1 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.